Phase 3 N=380 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
Breast Cancer
Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=500 Endotracheal Tube Securement Study
Mechanical Ventilation Complication
Primary: Rate of Any Incidence of the Following: Presence of Lip Ulcer, Endotracheal Tube Dislodgement, or Facial Skin Tears From the Time of Randomization to the Earlier of…
Phase 2 N=64 Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.
Bronchiectasis
Primary: Number of Participants Reporting Treatment-emergent AEs (TEAEs) up to End of Treatment — 2; 3; 2; 3 Participants
Phase 4 N=375 A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients
Restless Legs Syndrome (RLS)
Primary: Change From Baseline in International Restless Legs Syndrome Rating Scale (IRLS) Score at Week 12 — -10.5; -11.7 units on a scale — p=0.088
Phase 2 N=92 Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Brain and Central Nervous System Tumors
Primary: (Phase I) Maximum Tolerated Dose (MTD) of Hydroxychloroquine (HCQ) — 3; 7; 3; 0 Participants
Phase 4 N=181 Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction
Ureteral Obstruction
Primary: Ureteral Stent Symptom Questionnaire Score Up to 24 Hours Prior to Stent Insertion — 1.76; 1.84; 2.02; 1.93 score on a scale
N/A N=154 Spinal Control During Functional Activities to Improve Low Back Pain Outcomes
Mechanical Low Back Pain · Chronic Low Back Pain
Primary: Change in Modified Oswestry Disability Questionnaire (0-100%) From Baseline to Completion of Initial 6 Week Intervention Phase — 32.3; 32.6; 12.8; 21.2 score on a scale
N/A N=3 Pilot Study to Image the Esophagus Using a SECM Tethered Endoscopic Capsule
Healthy · Barrett's Esophagus · Gastric Acid Reflux
Primary: Feasibility for Imaging of Esophagus Using an SECM Tethered Endoscopic Capsule. — 3 Participants
Phase 4 N=34 Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia
Schizophrenia · Cigarette Smoking
Primary: Number of Participants Who Self-report Prolonged Abstinence — 6; 3 Participants
Phase 1 N=11 A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis
Chronic Kidney Disease, Secondary Hyperparathyroidism
Primary: Common Treatment-emergent Adverse Events — 2; 2; 2 Participants
Phase 1 N=57 Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus Placebo
Healthy
Primary: Total Cell Count of Neutrophils in Bronchoalveolar Lavage (BAL) Fluid After 24 Hours of the Segmental Lipopolysaccharide (LPS) Challenge — 687.02; 872.61…
Phase 3 N=243 A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Breast Cancer
Primary: Progression-Free Survival, as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) — 12.4; 14.5; 12.5; 16.5 months…
N/A N=78 Stress, Distress Intolerance, and Drug Dependence
Substance Dependence
Primary: Percentage of Positive Toxicology Swabs for Illicit Substances — 81.3; 79.1; 86.2; 82.3 percentage of positive toxicology screen
Phase 4 N=30 A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars
Keloid · Hypertrophic Scar · Cicatrix, Hypertrophic
Primary: Change in Lesion Volume — 40; 42; 32 Percent Change
N/A N=58 Hormones and Reduction in Co-users of Marijuana and Nicotine
Marijuana Dependence
Primary: Change in Marijuana Use as Defined by the TLFB — -1.7; -1.4; -0.9; -2.9 MJ use occasions per day